Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051974 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT00051974 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 155 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00051974, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
Conditions Studied
Interventions
- DRUG VELCADE™ (bortezomib) for Injection (formerly PS-341)
Study Locations (20)
Missouri
- DBA Kansas City Cancer Centers - Kansas City
- St. Louis University Health Sciences Center - St Louis
- Washington University, Barnard Cancer Center - St Louis
California
- Cedars-Sinai Comprehensive Cancer Center - Los Angeles
- UCLA Medical Center Thoracic Malignancy - Los Angeles
Florida
- Univeristy of Florida Shands Cancer Center - Gainesville
- Sylvester Comprehensive Cancer Center - Miami
Georgia
- Winship Cancer Institute - Atlanta
- Atlanta VAMC - Decatur
North Carolina
- Carolinas Hematology-Oncology Associates - Charlotte
- Duke University Medical Center - Durham
Alabama
- U of Alambama at Birmingham Comprehensive Cancer Center - Birmingham
Colorado
- University of Colorado Health Sciences Center - Aurora
Connecticut
- Yale University School Of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051974
The ClinicalTrials.gov registry entry for NCT00051974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which VELCADE™ (bortezomib) for Injection (formerly PS-341) is the first listed.
NCT00051974 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Missouri, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00051974 about?
NCT00051974 is a clinical study titled "Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
What is the current status of trial NCT00051974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2002-12.
What conditions does trial NCT00051974 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00051974?
The interventions under investigation include: VELCADE™ (bortezomib) for Injection (formerly PS-341) (DRUG).
Who is sponsoring clinical trial NCT00051974?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051974 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.